Name | Amlodipine + Olmesartan Medoxomil |
Classes |
Cardiovascular Agent Antihypertensive Antihypertensive Combination |
Diseases |
Angina Cardiovascular Disease Hypertension (High Blood Pressure) Myocardial Infarction |
Bangla
Amlodipine + Olmesartan Medoxomil
Amlodipine + Olmesartan Medoxomil is a combination medicine of amlodipine, a calcium channel blocker and valsartan, an angiotensin II type 1 receptor antagonist.
Amlodipine + Olmesartan Medoxomil is indicated for the treatment of essential hypertension. It is used to treat adults with high blood pressure who aren't obtaining significant improvement on amlodipine or valsartan alone.
- Patients who cannot regulate their blood pressure with 20 mg olmesartan medoxomil or 5 mg amlodipine alone may be given Olmesartan + Amlodipine 20 mg/5 mg.
- Patients whose blood pressure is not regulated properly by Olmesartan + Amlodipine 20 mg/5 mg may be given Olmesartan + Amlodipine 40 mg/5 mg.
- Patients whose blood pressure is not regulated effectively by Olmesartan + Amlodipine 40 mg/5 mg may be given Olmesartan + Amlodipine 40 mg/10 mg.
- Before switching to the fixed combination, a step-by-step titration of the individual component dosage is recommended. Direct switching from monotherapy to the fixed combination may be undertaken when clinically suitable.
- Patients getting separate tablets of olmesartan medoxomil and amlodipine may be switched to Olmesartan + Amlodipine tablets containing the same component doses for convenience.
Dosage Adjustment:
Renal impairment: Due to limited experience with larger dosages in this patient population, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatinine clearance of 20–60 mL/min) is 20 mg olmesartan medoxomil once daily. Sevikar should not be used in patients with severe renal impairment (creatinine clearance less than 20 mL/min).
Hepatic impairment: An initial dose of 10 mg olmesartan medoxomil once day is indicated for patients with moderate hepatic impairment, with a maximum dose of 20 mg once daily.
- During the second and third trimesters of pregnancy, medications that act on the renin-angiotensin system impair fetal renal function and increase fetal and newborn morbidity and death.
- 0.4 percent of patients with simple hypertension treated with Amlodipine + Omlesartan medoxomil experienced excessive hypotension. Angiotensin receptor blockers may cause symptomatic hypotension in individuals with an active renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics.
- In patients with heart failure or a recent myocardial infarction, as well as those undergoing surgery or dialysis, start therapy carefully.
Contraindication
Olmesartan + Amlodipine is contraindicated in patients hypersensitive to-
- Olmesartan or other ARBs, such as-
- Amlodipine or other dihydropyridines derivatives, such as-
Olmesartan + Amlodipine is contraindicated in the following health conditions-
- Severe hepatic problems
- Pregnancy
- Heart failure after acute myocardial infarction.